Recognized ligands |
Peptides |
Peptides |
Lipids |
Ligand processing |
Peptides derived from proteasomal degradation of proteins |
Peptides derived from lysosomal degradation of proteins |
Usually not required |
Ligand origin |
Endogenous |
Exogenous |
Exogenous or endogenous |
Ligand size and shape |
8–9 amino acids long peptides |
14–20 amino acids long peptides |
Different lipid types of varying shapes and sizes |
Binding site structure |
Closed-ended groove |
Open-ended groove |
Larger clefts of varying shapes and sizes, from dead-end single-pass tunnels to riddled maze-like structures |
Expression |
Most cell types |
Antigen-presenting cells |
CD1a-c mostly in antigen-presenting cells, CD1d more widely |
Degree of polymorphism |
Highly polymorphic |
Highly polymorphic |
Non-polymorphic |
Degree of polygenicity |
Highly polygenic |
Highly polygenic |
Non-polygenic (in humans) |
Responding T cells |
CD8+
|
CD4+
|
αβ, γδ, CD4+, CD8+ or double-negative (CD4−CD8−), iNKT, NKT type II |